Ardelyx
Develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.
Launch date
Employees
Market cap
€1.4b
Enterprise valuation
€1.3b (Public information from Sep 2024)
Share price
$5.9 ARDX
Fremont California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 7.6m | 10.1m | 52.2m | 124m | 304m | 393m | 547m |
| % growth | 43 % | 33 % | 417 % | 139 % | 144 % | 30 % | 39 % |
| EBITDA | (89.2m) | (154m) | (62.1m) | (55.4m) | (33.7m) | 6.6m | 152m |
| % EBITDA margin | (1178 %) | (1522 %) | (119 %) | (44 %) | (11 %) | 2 % | 28 % |
| Profit | (94.3m) | (158m) | (67.2m) | (66.1m) | (61.6m) | (41.1m) | 116m |
| % profit margin | (1246 %) | (1566 %) | (129 %) | (53 %) | (20 %) | (10 %) | 21 % |
| EV / revenue | 77.1x | 12.3x | 10.2x | 11.6x | 4.8x | 3.7x | 2.7x |
| EV / EBITDA | -6.5x | -0.8x | -8.6x | -26.0x | -43.2x | 220.4x | 9.6x |
| R&D budget | 65.1m | 91.1m | 35.2m | 35.5m | - | - | - |
| R&D % of revenue | 859 % | 903 % | 67 % | 29 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$26.1m | Series A | ||
| N/A | $5.0m | Debt | |
$30.0m | Series B | ||
| N/A | N/A | IPO | |
$77.8m | Post IPO Equity | ||
* | N/A | $86.3m | Post IPO Equity |
$110m | Post IPO Equity | ||
| N/A | $50.0m | Post IPO Debt | |
* | N/A | $125m | Post IPO Equity |
$27.5m | Post IPO Debt | ||
* | $20.0m | Post IPO Debt | |
* | $50.0m | Debt | |
| Total Funding | €51.0m | ||
Related Content
Recent News about Ardelyx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.